Biocompatible composite nanoparticles with large longitudinal relaxivity for targeted imaging and early diagnosis of cancer

Ma, Xuehua; Gong, An; Xiang, Lingchao; Chen, Tianxiang; Gao, Yuexia; Liang, Xing‐Jie; Shen, Zheyu; Wu, Aiguo

doi:10.1039/c3tb20648c

Cited by 58 publications

(75 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[Pro30 , Nle 31 , Bpa 32 , Leu 34 ]NPY(28−36) (IIe-Asn-Pro-Nle-Bpa-ArgLeu-Arg-Try-NH 2 ) was synthesized by the LifeTein LLC (Beijing, China). Rhodamine phalloidin (RP) and Hoechst 33342 were purchased from Invitrogen (Carlsbad, U.S.).…”

mentioning

confidence: 99%

Neuropeptide Y Y₁ Receptors Meditate Targeted Delivery of Anticancer Drug with Encapsulated Nanoparticles to Breast Cancer Cells with High Selectivity and Its Potential for Breast Cancer Therapy

Shen

et al. 2015

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

By enabling nanoparticle-based drug delivery system to actively target cancer cells with high selectivity, active targeted molecules have attracted great attention in the application of nanoparticles for anticancer drug delivery. However, the clinical application of most active targeted molecules in breast cancer therapy is limited, due to the low expression of their receptors in breast tumors or coexpression in the normal and tumor breast tissues. Here, a neuropeptide Y Y1 receptors ligand PNBL-NPY, as a novel targeted molecule, is conjugated with anticancer drug doxorubicin encapsulating albumin nanoparticles to investigate the effect of Y1 receptors on the delivery of drug-loaded nanoparticles to breast cancer cells and its potential for breast cancer therapy. The PNBL-NPY can actively recognize and bind to the Y1 receptors that are significantly overexpressed on the surface of the breast cancer cells, and the drug-loaded nanoparticles are delivered directly into the cancer cells through internalization. This system is highly selective and able to distinguish the breast cancer cells from the normal cells, due to normal breast cells that express Y2 receptors only. It is anticipated that this study may provide a guidance in the development of Y1 receptor-based nanoparticulate drug delivery system for a safer and more efficient breast cancer therapy.

show abstract

mentioning

confidence: 99%

Neuropeptide Y Y₁ Receptors Meditate Targeted Delivery of Anticancer Drug with Encapsulated Nanoparticles to Breast Cancer Cells with High Selectivity and Its Potential for Breast Cancer Therapy

Shen

et al. 2015

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

show abstract

“…This is consistent with the literature results. 19,26 The hydrodynamic diameter of GONs is 8.71±2.78 nm ( Figure 1B); this increase in size is due to the formed hydration corona. We measured the zeta potential of the GONs (52.6 mV).…”

Section: Characteristics Of Gonsmentioning

confidence: 98%

“…The Gd concentration was measured by inductively coupled plasma atomic emission spectrometry on an IRIS ER/S (Thermo Jarrell Ash, USA) using an external calibration method. 19 To obtain cellular Gd concentrations, the cells were pretreated with various concentrations (0.5, 1.0, 5.0, 10.0, and 20.0 µg/mL) of Gd for 24 hours. The cells were harvested, counted, and dried, and then resuspended and ionized in 1.0 mL of aqua regia.…”

Section: Gd Concentration Analysismentioning

confidence: 99%

“…17 GONs have been developed as advanced T 1 -weighted MRI contrast agents due to their high longitudinal relaxivities and small r 2 /r 1 ratios. [18][19][20] The radiosensitization properties of GONs were first investigated by Amirrashedi et al in a gel-filled phantom, in which the maximum dose enhancement of GONs ranged from 15% to 24%. 21 Seo et al found that the GONs enhancement of the production of ROS under photon and proton irradiation was dose-dependent with a factor of 1.94 compared with that of the radiation-only control.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Ultra-small gadolinium oxide nanocrystal sensitization of non-small-cell lung cancer cells toward X-ray irradiation by promoting cytostatic autophagy</p>

Li¹,

Li²,

Jiang³

et al. 2019

IJN

View full text Add to dashboard Cite

Background Gadolinium-based nanoparticles (GdNPs) have been used as theranostic sensitizers in clinical radiotherapy studies; however, the biomechanisms underlying the radio-sensitizing effects of GdNPs have yet to be determined. In this study, ultra-small gadolinium oxide nanocrystals (GONs) were employed to investigate their radiosensitizing effects and biological mechanisms in non-small-cell lung cancer (NSCLC) cells under X-ray irradiation. Method and materials GONs were synthesized using polyol method. Hydroxyl radical production, oxidative stress, and clonogenic survival after X-ray irradiation were used to evaluate the radiosensitizing effects of GONs. DNA double-strand breakage, cell cycle phase, and apoptosis and autophagy incidences were investigated in vitro to determine the radiosensitizing biomechanism of GONs under X-ray irradiation. Results GONs induced hydroxyl radical production and oxidative stress in a dose- and concentration-dependent manner in NSCLC cells after X-ray irradiation. The sensitizer enhancement ratios of GONs ranged between 19.3% and 26.3% for the NSCLC cells under investigation with a 10% survival rate compared with that of the cells treated with irradiation alone. Addition of 3-methyladenine to the cell medium decreased the incidence rate of autophagy and increased cell survival, supporting the idea that the GONs promoted cytostatic autophagy in NSCLC cells under X-ray irradiation. Conclusion This study examined the biological mechanisms underlying the radiosensitizing effects of GONs on NSCLC cells and presented the first evidence for the radiosensitizing effects of GONs via activation of cytostatic autophagy pathway following X-ray irradiation.

show abstract

“…Wu and co-workers encapsulated Gd 2 O 3 nanoparticles into albumin, which were cross-linked with glutaraldehyde and found to exhibit autofluorescence. 134 Folic acid was then conjugated onto the surface, and cancer cell targeting was realized.…”

Section: 2mentioning

confidence: 99%

Lanthanide Nanoparticles: From Design toward Bioimaging and Therapy

et al. 2015

View full text Add to dashboard Cite

Biocompatible composite nanoparticles with large longitudinal relaxivity for targeted imaging and early diagnosis of cancer

Cited by 58 publications

References 41 publications

Neuropeptide Y Y₁ Receptors Meditate Targeted Delivery of Anticancer Drug with Encapsulated Nanoparticles to Breast Cancer Cells with High Selectivity and Its Potential for Breast Cancer Therapy

Neuropeptide Y Y₁ Receptors Meditate Targeted Delivery of Anticancer Drug with Encapsulated Nanoparticles to Breast Cancer Cells with High Selectivity and Its Potential for Breast Cancer Therapy

<p>Ultra-small gadolinium oxide nanocrystal sensitization of non-small-cell lung cancer cells toward X-ray irradiation by promoting cytostatic autophagy</p>

Lanthanide Nanoparticles: From Design toward Bioimaging and Therapy

Contact Info

Product

Resources

About

Biocompatible composite nanoparticles with large longitudinal relaxivity for targeted imaging and early diagnosis of cancer

Cited by 58 publications

References 41 publications

Neuropeptide Y Y1 Receptors Meditate Targeted Delivery of Anticancer Drug with Encapsulated Nanoparticles to Breast Cancer Cells with High Selectivity and Its Potential for Breast Cancer Therapy

Neuropeptide Y Y1 Receptors Meditate Targeted Delivery of Anticancer Drug with Encapsulated Nanoparticles to Breast Cancer Cells with High Selectivity and Its Potential for Breast Cancer Therapy

<p>Ultra-small gadolinium oxide nanocrystal sensitization of non-small-cell lung cancer cells toward X-ray irradiation by promoting cytostatic autophagy</p>

Lanthanide Nanoparticles: From Design toward Bioimaging and Therapy

Contact Info

Product

Resources

About

Neuropeptide Y Y₁ Receptors Meditate Targeted Delivery of Anticancer Drug with Encapsulated Nanoparticles to Breast Cancer Cells with High Selectivity and Its Potential for Breast Cancer Therapy

Neuropeptide Y Y₁ Receptors Meditate Targeted Delivery of Anticancer Drug with Encapsulated Nanoparticles to Breast Cancer Cells with High Selectivity and Its Potential for Breast Cancer Therapy